Original from: Digital Health News
Bengaluru-based deep-tech startup Morphle Labs has raised USD 5 million in a Series A round led by Inflexor Ventures to expand its physical AI-based automation systems for cancer diagnostics.
The funding will support global market expansion, scale manufacturing of its flagship platforms RoboTome® and MorphoLens, and push forward regulatory approvals across major international markets.
Founded in 2017, Morphle Labs builds automation systems for histopathology, one of the most manual and resource-constrained domains in cancer diagnostics. Even as radiology and hematology have advanced toward digitization, anatomic pathology continues to depend on labour-intensive workflows. Globally, more than 60% of histopathology labs report unfilled positions, contributing to diagnostic delays and increasing case backlogs. Morphle aims to address these gaps by integrating robotics, precision hardware, optics, and computer vision into end-to-end diagnostic workflows.
The company’s robotic microtomy system, RoboTome®, is designed to slice biopsy blocks at more than twice the speed of trained histotechnologists while maintaining consistent section quality. Its imaging platform, MorphoLens, digitises over 100 slides per hour using high-throughput optics and AI-driven imaging, enabling remote review and scalable pathology operations. Together, the systems automate key manual steps in tissue processing. Morphle has filed over 80 patents across robotics, imaging, embedded systems, and precision hardware.
Rohit Hiwale, Founder and CEO of Morphle Labs, said the company aims to rebuild histology workflows through advanced automation. He noted that the platforms address core bottlenecks in microtomy and slide imaging, forming the foundation for broader diagnostic automation.
The company plans to significantly expand hiring across robotics, computer vision, optics, hardware engineering, medical-grade software, and regulatory compliance as it strengthens its team in Bengaluru and Boston. It is also investing in scaling its technology stack in physical AI—an approach that combines intelligent software with high-fidelity hardware for medical applications.
Pratip Mazumdar, Partner at Inflexor Ventures, said Morphle’s traction in the U.S. and Europe reflects the scale of demand for automated histopathology systems and the company’s ability to build clinically reliable solutions.
Source: Morphle Labs Secures $5M Series A to Accelerate Robotic Cancer Diagnostics Expansion
China Association of In-vitro Diagnostics
Part of the information in our website is from the internet.
If by any chance it violates your rights, please contact us.